On Tuesday, Midway Gold Corp (USA) (NYSEMKT:MDW)’s shares declined -9.82% to $0.252.
Midway Gold Corp (USA) (MDW) declared results on modeling work at the Pan Gold Mine in Nevada. Completion of the updated mineral resource study for Pan allows us to move forward with optimizing the mine plan, updating reserves and making operational changes that will allow us to advance the Pan Mine.
Highlights of 2015 Updated Resource Study and Production Update
- The improved understanding of the geologic controls on mineralization resulted in a noteworthychange in the classification of the Pan Resource from Measured and Indicated into the Inferred category. Future drilling should enable us to move Inferred ounces to Measured and Indicated ounces.
The updated mineral resource for the Pan Project is estimated by Gustavson Associates, LLC (“Gustavson”) to be 35.9 million tonnes grading an average of 0.44 g/t Au classified as a measured and indicated mineral resource. An additional 13.9 million tonnes grading an average of 0.31 g/t Au are classified as an inferred mineral resource. All of the estimated resources are based on a 0.14 g/t cutoff.
Production continues to ramp up with about 4,300 ounces of gold produced to date. We presently have about 36,000 contained ounces of gold on the heap leach pad and most of the pad is presently under leach.
YY Inc (ADR) (NASDAQ:YY)’s shares dropped -8.55% to $63.07.
YY Inc (ADR) (YY) declared its unaudited financial results for the first quarter ended March 31, 2015.
First Quarter 2015 Highlights
- Net revenues raised by 72.6% to RMB1,150.3 million (US$185.6 million) from RMB666.3 million in the corresponding period of 2014.
- Net income attributable to YY Inc. raised by 23.6% to RMB227.0 million (US$36.5 million) from RMB183.6 million in the corresponding period of 2014.
- Non-GAAP net income attributable to YY Inc.1raised by 24.7% to RMB258.8 million (US$41.6 million) from RMB207.6 million in the corresponding period of 2014.
YY Inc., through its auxiliaries, operates an online social platform in the Peoples Republic of China. It engages users in real-time online group activities through voice, video, and text on personal computers and mobile devices; and enables users to create and organize groups of various sizes to discover and take part in a range of online activities, counting music shows, online games, dating shows, live games broadcasting, and e-learning.
At the end of Tuesday’s trade, Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI)‘s shares dipped -8.16% to $9.00.
Plasmatech Biopharmaceuticals Inc (PTBI) declared that it closed the formerly declared equity financing of $10 million of common stock at a price of $8.00 per share, or 1,250,000 shares, and warrants to purchase 625,000 shares of common stock. The warrants have an exercise price of $10.00 per share and are exercisable for 30 months from the closing date. Proceeds from the financing will be used to support continued development of its programs in orphan diseases, potential expansion of its portfolio in other rare disease programs, working capital and general corporate purposes.
PlasmaTech Biopharmaceuticals, Inc. operates as a biopharmaceutical company and develops protein biologic therapies and oncology supportive care products. The company’s marketed product comprises MuGard the administration of oral mucositis; and ProctiGard for the treatment of radiation proctitis, a frequent side effect of radiation treatment to the pelvic region.
Diplomat Pharmacy Inc (NYSE:DPLO), ended its Tuesday’s trading session with -7.86% loss, and closed at $33.27.
Diplomat Pharmacy Inc (DPLO) declared financial results for the quarter ended March 31, 2015. All comparisons, unless otherwise noted, are to the quarter ended March 31, 2014.
First Quarter 2015 Highlights comprise:
- Revenue of $625 million, an enhance of 34%
- Total prescriptions dispensed of 194,000, an enhance of 6%
- Gross margin of 6.6% as compared to 6.3%
- Adjusted EBITDA of $11.2 million, an enhance of 36%
- Adjusted EPS of $0.09, as compared to $0.05
First Quarter Financial Summary:
Revenue for the first quarter of 2015 was $624.9 million, contrast to $465.7 million in the first quarter of 2014, an enhance of $159.2 million or 34%. The enhance was the result of about $58 million of revenue from drugs that were new to the market or newly dispensed by Diplomat and about $24 million from our acquisitions. The remaining enhance is primarily attributable to a richer mix of high-priced drugs, the impact of manufacturer price enhances and payor mix changes.
Gross profit in the first quarter of 2015 was $41.1 million, contrast to $29.5 million in the first quarter of 2014 and generated gross margin of 6.6% contrast to 6.3%. The gross margin improvement in the quarter was driven by drug mix changes, counting the impact of the acquisitions, and continued favorable pricing trends.
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, preceding authorization, risk evaluation and medication strategy, retail specialty, and hub services, in addition to clinical and administrative support services to hospitals and health systems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
